Drug Drug Interaction Study for EYP001 With Entecavir
Status:
Completed
Trial end date:
2018-07-20
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single-center, open-label, three subsequent dosing periods study to
evaluate the drug-drug-interaction (DDI), pharmaco-kinetics (PK) and pharmacodynamics (PD),
safety, and tolerability of a single dose of EYP100a combined with ETV in healthy men and
women dosed in the morning under fasted conditions.